Free cash flow is negative, the Rule of 40 fails at negative 94, a Piotroski F-Score of 3 out of 9 reflects broad financial weakness, and a single approved product carries all commercial risk; with only 1.9% headroom to the near-term resistance target and an unfavorable risk/reward, two recent earnings beats introduce modest optimism but do not yet support an attractive setup at current prices.
Thesis pillars
- Single Product Concentration Risk↑Improving
- Minimal Upside Unfavorable Setup→Stable
- Negative Fcf Weak Fundamentals→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Nov 25, 2025
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $60.21: Concentration risk — Product: single approved product; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1).
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform, with REDEMPLO (plozasiran) receiving FDA approval in November 2025 for Familial Chylomicronemia Syndrome as its first commercial product, plus 18 drug candidates in clinical trials. Revenue... Read more
Sell if holding. Multiple concerning factors at $60.21: Concentration risk — Product: single approved product; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: Death cross but MACD improving, RSI 48. Score 6.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 26d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Arrowhead Pharmaceuticals, Inc.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals' first commercial product, REDEMPLO (plozasiran), received FDA approval in November 2025 as the first and only siRNA treatment for Familial Chylomicronemia Syndrome. The company held 18 drug candidates in clinical trials at the time of filing—including Phase 3 studies for severe hypertriglyceridemia—and maintained collaboration agreements with Takeda, GSK, Amgen, Sarepta, and Novartis, which provide non-dilutive capital to support the wholly-owned pipeline through commercialization.
Arrowhead generates revenue through REDEMPLO product sales and licensing and collaboration payments from partners. The Takeda agreement for fazirsiran (ARO-AAT) provides co-development funding and a 50/50 U.S. profit share if approved; outside the United States, Takeda holds an exclusive license and Arrowhead is eligible for 20-25% tiered royalties on net sales. Amgen owns olpasiran (ARO-LPA), a lipoprotein(a)-targeting siRNA in Phase 3 for cardiovascular disease; Arrowhead sold its royalty rights to Royalty Pharma but remains eligible for up to $485 million in remaining milestone payments from Amgen and Royalty Pharma combined. The Sarepta agreement executed in November 2024 covers multiple clinical and preclinical muscle, CNS, and lung programs. The Novartis agreement executed in August 2025 and closed October 2025 covers ARO-SNCA for synucleinopathies including Parkinson's disease. Manufacturing for clinical supplies and commercial products depends on third-party contract manufacturers, as Arrowhead holds limited internal manufacturing capacity.
Show full overview
The plozasiran program carries a distinct Phase 3 readout event beyond the FCS label: SHASTA-3, SHASTA-4, and SHASTA-5 studies for severe hypertriglyceridemia were fully enrolled at the time of filing, with a supplemental NDA planned for 2026 pending successful completion. The 10-K explicitly notes that REDEMPLO's Phase 3 PALISADE success in FCS does not guarantee approval in sHTG because endpoints and clinical data requirements differ between a rare-disease indication and a broader patient population.
See also: Healthcare · Biotechnology
From Arrowhead Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — Arrowhead Pharmaceuticals, Inc.
Latest news
- NEWS Arrowhead (ARWR) Stock Outlook | Q1 2026: Profit Disappoints - PEG Ratio - Newser — Newser negative
- NEWS Arrowhead (ARWR) Stock Outlook | Q1 2026: Profit Disappoints - Event Driven - Newser — Newser neutral
- NEWS Why Arrowhead Pharmaceuticals (ARWR) Is Up 6.8% After Australia Approves First-In-Class FCS Therapy REDEMPLO - simplywal — simplywall.st positive
- NEWS JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com — TIKR.com positive
- NEWS ARWR rallies 7% this week as Europe edges closer to Redemplo approval amid analyst optimism - MSN — MSN positive
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsingle approved product10-K Item 1A: 'we have only one product based on RNAi and our delivery technologies approved in November 2025'
- MEDIUMSupplierthird-party manufacturers10-K Item 1A: 'must rely on third-party manufacturers to manufacture certain of our clinical supplies and our commercial products'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $60.21: Concentration risk — Product: single approved product; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: Death cross but MACD improving, RSI 48. Prior stop was $56.00. Score 6.1/10, moderate confidence.
Analyst target: $93.71 (+55.6% upside). Prior stop was $56.00. Stop-loss: $56.00.
Concentration risk — Product: single approved product; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1); Leverage penalty (D/E 3.0): -1.5.
Arrowhead Pharmaceuticals, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 6.0/10. Verdict: Sell.
21 analysts cover ARWR with a consensus score of 4.3/5. Average price target: $108.
What does Arrowhead Pharmaceuticals, Inc. do?Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform, with REDEMPLO (plozasiran)...
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform, with REDEMPLO (plozasiran) receiving FDA approval in November 2025 for Familial Chylomicronemia Syndrome as its first commercial product, plus 18 drug candidates in clinical trials. Revenue flows from REDEMPLO product sales and licensing and collaboration agreements with Takeda, GSK, Amgen, Sarepta, and Novartis.